Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesVeterinary Medicine

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536081

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536081

Porcine Vaccines

PUBLISHED:
PAGES: 376 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

Global Porcine Vaccines Market to Reach US$3.0 Billion by 2030

The global market for Porcine Vaccines estimated at US$2.2 Billion in the year 2023, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Inactivated Vaccines Technology, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Recombinant Vaccines Technology segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$586.7 Million While China is Forecast to Grow at 8.4% CAGR

The Porcine Vaccines market in the U.S. is estimated at US$586.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$634.0 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Porcine Vaccines Market - Key Trends and Drivers Summarized

Porcine vaccines are critical tools in the management and control of infectious diseases in swine populations, safeguarding animal health and enhancing the efficiency of pork production. These vaccines help in preventing a range of diseases, including classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and swine influenza, among others. The importance of porcine vaccines is underscored by the significant economic impacts these diseases can have on the pork industry through losses in productivity and high mortality rates. Effective vaccination programs are essential for maintaining the health of swine herds and ensuring the production of high-quality pork products. Moreover, the use of vaccines in swine helps reduce the need for antibiotics, which is crucial in the fight against antimicrobial resistance. Manufacturers have developed both live attenuated and inactivated vaccines, which can be administered via various routes, including injection, oral, and nasal applications, tailored to maximize efficacy and ease of use in diverse farming environments.

The development and enhancement of porcine vaccines have been influenced heavily by advances in biotechnology and veterinary sciences. Modern diagnostic tools and genetic sequencing techniques have enabled better identification and understanding of swine pathogens, leading to more targeted vaccine development. This precision not only improves the effectiveness of vaccines but also reduces potential side effects, enhancing animal welfare. Another trend is the rise in the use of combination vaccines that target multiple pathogens in a single formulation, simplifying vaccination schedules and reducing stress on animals. Additionally, there is a growing emphasis on the development of thermostable vaccines that do not require refrigeration, making them particularly valuable in rural or under-resourced regions where cold chain infrastructure is lacking. These innovations have expanded the accessibility and impact of vaccination programs worldwide, contributing to the overall health and productivity of swine industries.

The growth in the porcine vaccines market is driven by several factors, including the increasing prevalence of swine diseases, global expansion of pork production, and heightened awareness among farmers about the benefits of vaccination. The spread of intensive pig farming and the consequent rise in disease transmission risks necessitate robust vaccination protocols. Economic growth in emerging markets has led to increased demand for pork, incentivizing producers to invest in health management practices, including vaccination, to boost yields and profitability. Furthermore, regulatory policies promoting animal health and food safety have mandated the use of vaccines in many countries, reinforcing market growth. Advances in vaccine technology, such as the development of DNA vaccines and the use of adjuvants to enhance immune responses, also play a critical role. Collectively, these drivers are shaping a vibrant market landscape, highlighting the importance of continued innovation and adaptation in vaccine development to meet the evolving challenges in swine health management.

Select Competitors (Total 86 Featured) -

  • Bimeda Biologicals Inc.
  • Boehringer Ingelheim Animal Health USA Inc.
  • Ceva Sante Animale
  • Elanco Animal Health
  • Endovac Animal Health
  • ICAR-Indian Veterinary Research Institute (ICAR-IVRI)
  • Indian Immunologicals Ltd.
  • Laboratorios HIPRA SA (HIPRA)
  • Merck Animal Health
  • Phibro Animal Health Corporation
  • Shandong Sinder Technology Co., Ltd.
  • Vaxxinova International
  • Vetoquinol S.A.
  • Zoetis, Inc.;
Show more
Product Code: MCP26632

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Porcine Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Swine Diseases Drives Demand for Porcine Vaccines
    • Increasing Focus on Animal Health and Welfare Strengthens Market Growth
    • Expansion of Commercial Pig Farming Spurs Market Demand
    • Rising Consumer Demand for Safe and Healthy Pork Propels Market Growth
    • Increasing Awareness Among Farmers About Disease Prevention Drives Adoption
    • Expansion of Veterinary Healthcare Infrastructure Bodes Well for Market Growth
    • Growing Trend of Biosecurity Measures in Pig Farming Expands Addressable Market
    • Rising Adoption of Combination Vaccines Drives Market Demand
    • Expansion of Livestock Insurance Programs Propels Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Porcine Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Porcine Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Porcine Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Porcine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Inactivated Vaccines Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Inactivated Vaccines Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Inactivated Vaccines Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Vaccines Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Recombinant Vaccines Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Recombinant Vaccines Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Live Attenuated Vaccines Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Live Attenuated Vaccines Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Live Attenuated Vaccines Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for DNA Vaccines Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for DNA Vaccines Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for DNA Vaccines Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Technology Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Technology Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Technology Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hog Production Farms End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hog Production Farms End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hog Production Farms End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Veterinary Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Veterinary Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Veterinary Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Intravenous Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Intramuscular Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Intramuscular Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Intramuscular Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • JAPAN
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • CHINA
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • EUROPE
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Porcine Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Porcine Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Porcine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • FRANCE
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • GERMANY
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Porcine Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Porcine Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Porcine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • INDIA
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Porcine Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Porcine Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Porcine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Porcine Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Porcine Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Porcine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030
  • AFRICA
    • Porcine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Porcine Vaccines by Technology Type - Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Porcine Vaccines by Technology Type - Percentage Breakdown of Value Sales for Inactivated Vaccines Technology, Recombinant Vaccines Technology, Live Attenuated Vaccines Technology, DNA Vaccines Technology and Other Technology Types for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Porcine Vaccines by End-Use - Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Porcine Vaccines by End-Use - Percentage Breakdown of Value Sales for Hog Production Farms End-Use, Other End-Uses and Veterinary Hospitals End-Use for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Porcine Vaccines by Route Of Administration - Intravenous Administration, Intramuscular Administration and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Porcine Vaccines by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Other Routes of Administration for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!